NEW YORK (GenomeWeb News) – Becton Dickinson today said fiscal third-quarter revenue increased 7 percent as R&D costs soared 42 percent and income grew 9 percent.
 
Receipts for the three months ended June 30 increased to $1.5 billion from $1.4 billion year over year.
 
The BD Biosciences segment reported the strongest growth, as revenues increased 9 percent to $219 million. Sales of flow cytometry instruments, reagents, and cell imaging products contributed to the rise.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The US National Institutes of Health and the Food and Drug Administration have proposed changing gene therapy oversight, the Associated Press reports.

Nature News reports that the Salk Institute has asked for the scope of a gender discrimination lawsuit brought against it to be narrowed.

CNBC reports that the sequencing startup Veritas aims to sequence individuals who fall at extremes.

In PLOS this week: genotyping of indigenous North African goats, program to simulate evolve and resequencing studies, and more.